Contents

Search

pertuzumab (Perjeta)

Indications: - Her2-positive metastatic breast cancer, in combination with trastuzumab & docetaxel (FDA-approved 6-8-12)* - early stage breast cancer prior to surgery [3] - increases likelihood of being cancer=free 12 weeks after surgery by 18% [3] * addition of pertuzumab to docetaxel & trastuzumab as a 1st-line treatment for HER2-positive metastatic breast cancer is associated with 16 months longer survival (57 months vs 41 months) [4] * NICE rejects adjuvant pertuzumab in HER2(+) breast cancer; may not offer meaningful benefit [5] Dosage: - loading dose of 840 mg, followed by 420 mg every 3 weeks until disease progression or the development of unmanageable toxicity Adverse effects: - minimal additional adverse effects with the addition of pertuzumab to trastuzumab & docetaxel Mechanism of action: - pertuzumab is a humanized monoclonal antibody that binds HER2 (at a different site than trastuzumab) & stimulates antibody-dependent, cell-mediated cytotoxicity - synergy with trastuzumab

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

antineoplastic monoclonal antibody

References

  1. CLEOPATRA (CLinical Evaluation Of PertuzumAb and TRAstuzumab) trial: 34th Annual San Antonio Breast Cancer Symposium (SABCS): Abstract S5-5. Presented December 9, 2011
  2. FDA News Release: June 8, 2012 FDA approves Perjeta for type of late-stage breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm307549.htm
  3. Physician's First Watch, September 13, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - Yahoo Nesw. Associated Press. FDA panel backs drug for early-stage breast cancer http://news.yahoo.com/fda-panel-backs-drug-early-stage-breast-cancer-185302129--finance.html - FDA News Release: Sept. 30, 2013 FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm
  4. Young K, Sadoughi S, Sofair A Physician's First Watch, September 29, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - European Society of Medical Oncology (ESMO) 2014 Abstract 3500_Pr- Final overall survival (OS) analysis from the CLEOPATRIA studi of the first-line (1L) pertuzimab (Ptz), traztuzumab (T), and doxetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). https://www.webges.com/cslide/library/esmo/browse/itinerary/478/2014-09-28#9f9n02vU
  5. MedPage Today Staff NICE Rejects Adjuvant Perjeta in HER2 Breast Cancer. In contrast with FDA, Britain's cost watchdog says drug may not offer 'meaningful' benefit. MedPage Today. June 14, 2018 https://www.medpagetoday.com/hematologyoncology/breastcancer/73509

Component-of

hylenex/pertuzumab/trastuzumab pertuzumab/trastuzumab with hyaluronidase (Phesgo)